文献速递前列腺癌

评估临床风险分层以确定高危局限性前列腺癌患者从长期与短期雄激素剥夺治疗中的获益

Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-01-08

基于ICECaP数据库中3项随机试验的2780例患者,评估临床风险分层能否判断高危局限性前列腺癌患者从长期雄激素剥夺治疗(ltADT)与短期雄激素剥夺治疗(stADT)中的获益差异;结果显示极高危患者从ltADT中获益更大,但风险组间治疗效应差异无统计学意义,结论认为该分层需在临床试验中进一步评估。

要点

  • 极高危患者接受ltADT对比stADT的MFS HR为0.77(0.68-0.88),高危患者为0.89(0.76-1.03)。
  • 风险组间治疗效应差异无统计学意义(交互作用p>0.1)。
  • 极高危组跨试验治疗效应异质性低,高危组为中等。

核心结论

  • 临床风险分层需在临床试验中进一步评估,以识别哪些高危局限性前列腺癌患者可能从ltADT对比stADT中获益。

研究设计与样本

  • 查询ICECaP数据库中随机试验的汇总数据,纳入3项试验共2780例患者。
  • 采用分层Cox回归和Gray回归获得总体治疗效应及风险组效应,Wald交互检验评估治疗获益是否因风险组或试验而异。
  • 采用Cochran Q检验和I2评估研究间异质性。

主要发现

  • 极高危患者对比高危患者接受ltADT的MFS HR为0.77(0.68-0.88)vs 0.89(0.76-1.03)。
  • 极高危患者对比高危患者接受ltADT的TTM HR为0.61(0.51-0.74)vs 0.77(0.59-0.99)。
  • 极高危患者对比高危患者接受ltADT的PCSM HR为0.71(0.56-0.90)vs 0.82(0.59-1.14)。
  • 极高危患者对比高危患者接受ltADT的OS HR为0.87(0.76-1.00)vs 0.93(0.79-1.08)。
  • 按风险组划分的治疗效应差异无统计学意义(交互作用p>0.1)。

关键数值与推荐

  • 高危定义为具有1个高危因素(Gleason≥8、PSA>20 ng/mL、≥cT3中任一)。
  • 极高危定义为具有2-3个高危因素和/或cN1疾病。

临床怎么用

  • 原文结论未据此给出推荐,仅指出临床风险分层需在临床试验中进一步评估。

局限性

  • 极高危组跨试验治疗效应异质性低,高危组为中等。
  • 作者结论指出临床风险分层需在临床试验中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients treated with RT and long-term androgen deprivation therapy (ltADT) for high-risk localized prostate cancer (HRLPC) with 1 high-risk factor (any of Gleason ≥8, PSA > 20 ng/mL, ≥cT3; "high-risk") have better outcomes than those with 2-3 factors and/or cN1 disease ("very high risk"). We evaluated whether this risk stratification could determine benefit from ltADT versus short-term (stADT). METHODS: The Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) repository of randomized trials was queried to identify eligible patients and trials. The key outcomes of interest were metastasis-free survival (MFS), overall survival (OS), time to metastasis (TTM) and prostate cancer-specific mortality (PCSM). Stratified Cox and Gray's regression were used to obtain the overall treatment effect for outcomes and risk groups, and the Wald interaction test to estimate whether treatment benefit differed by risk group or trial. Heterogeneity of studies was assessed by Cochran's Q and I2. RESULTS: 2780 patients from 3 trials were included. Patients with very-high risk disease had greater benefit with ltADT compared to high-risk disease (MFS HR 0.77 [0.68-0.88] vs. 0.89 [0.76-1.03]; TTM 0.61 [0.51-0.74] vs. 0.77 [0.59-0.99]; PCSM 0.71 [0.56-0.90] vs. 0.82 [0.59-1.14]; OS 0.87 [0.76-1.00] vs. 0.93 [0.79-1.08]), but there was no statistically significant difference in treatment effect by risk group (p-interaction >0.1). Heterogeneity for treatment effect across trials was low in the very high-risk group and moderate in the high-risk group. CONCLUSIONS: Clinical risk stratification merits further evaluation in clinical trials to identify which patients with HRLPC may benefit from ltADT versus stADT.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ravi P, Xie W, Gillessen S, et al. Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 39779964. doi:10.1038/s41391-025-00937-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。